Get started
Eli Lilly and Company Canadian Depositary ReceiptEli Lilly and Company Canadian Depositary ReceiptEli Lilly and Company Canadian Depositary Receipt

Eli Lilly and Company Canadian Depositary Receipt

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsSeasonalsBonds

LLY0 chart


Full chart

Key facts today


Eli Lilly's weight-loss drug Mounjaro has doubled sales in India, while the company braces for competition as the patent for Wegovy's key ingredient, semaglutide, expires next year.
Eli Lilly is investing $27 billion to adapt to trade rules and boost local supply capabilities amid rising demand for its pharmaceuticals.
Eli Lilly is testing muscle growth treatments, partnering with Scholar Rock and assessing combinations with Novo Nordisk drugs. The market for these therapies could surpass $30 billion by 2035.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪677.15 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
52.738
Basic EPS (TTM)
0.360 EUR
Net income (FY)
‪9.74 B‬ EUR
Revenue (FY)
‪41.42 B‬ EUR
Shares float
—
Beta (1Y)
—

Employees


Employees (FY)
‪47 K‬
Change (1Y)
‪+4 K‬ +9.30%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Eli Lilly and Company


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David A. Ricks
Website
lilly.com
Headquarters
Indianapolis
Founded
1876
ISIN
CA28655A1066
FIGI
BBG01LNVJNH9
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Check out other big names from the same industry as LLY0.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

LLY0 news



Ideas



See all ideas 

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

LLY0 highest yielding bonds


XS238628644
Eli Lilly and Company 1.625% 14-SEP-2043
Yield to maturity
5.89%
Maturity date
Sep 14, 2043
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044
Yield to maturity
5.65%
Maturity date
Jun 15, 2044
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065
Yield to maturity
5.45%
Maturity date
Oct 15, 2065
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065
Yield to maturity
5.43%
Maturity date
Feb 12, 2065
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064
Yield to maturity
5.43%
Maturity date
Feb 9, 2064
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
Yield to maturity
5.43%
Maturity date
Feb 27, 2063
US532457BU1
Eli Lilly and Company 4.15% 15-MAR-2059
Yield to maturity
5.43%
Maturity date
Mar 15, 2059
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064
Yield to maturity
5.43%
Maturity date
Aug 14, 2064
US532457BT4
Eli Lilly and Company 3.95% 15-MAR-2049
Yield to maturity
5.36%
Maturity date
Mar 15, 2049
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054
Yield to maturity
5.36%
Maturity date
Feb 9, 2054
LLY4492882
Eli Lilly and Company 3.95% 15-MAY-2047
Yield to maturity
5.35%
Maturity date
May 15, 2047

See all LLY0 bonds 

Sparks


Curated watchlists where LLY0 is featured.

See all sparks 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on DUS exchange Eli Lilly and Company Canadian Depositary Receipt stocks are traded under the ticker LLY0.
LLY0 reached its all-time high on Aug 21, 2024 with the price of 25.200 EUR, and its all-time low was 13.600 EUR and was reached on Aug 11, 2025. View more price dynamics on LLY0 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Eli Lilly and Company Canadian Depositary Receipt financials in yearly and quarterly reports right on TradingView.
LLY0 net income for the last quarter is ‪4.88 B‬ EUR, while the quarter before that showed ‪2.54 B‬ EUR of net income which accounts for 92.08% change. Track more Eli Lilly and Company Canadian Depositary Receipt financial stats to get the full picture.
No, LLY0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 7, 2025, the company has ‪47 K‬ employees. See our rating of the largest employees — is Eli Lilly and Company Canadian Depositary Receipt on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company Canadian Depositary Receipt EBITDA is ‪21.17 B‬ EUR, and current EBITDA margin is 41.75%. See more stats in Eli Lilly and Company Canadian Depositary Receipt financial statements.
Like other stocks, LLY0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company Canadian Depositary Receipt stock right from TradingView charts — choose your broker and connect to your account.